NRG-GU003

A Randomized Phase III Trial of Hypofractionated Post-Prostatectomy Radiation Therapy (HYPORT) Versus Conventional Post-Prostatectomy Radiation Therapy (COPORT)

Principal Investigator

Mark Buyyounouski

Status

Disease Site

Genitourinary [GU] Prostate

Phase

III

Developmental Therapeutics

No

Primary Objective

The primary objective is to demonstrate that hypofractionated post-prostatectomy radiotherapy (HYPORT) does not increase patient-reported GI and GU symptoms  over conventionally fractionated post-prostatectomy (COPORT) at the 2-year time point.

Patient Population

Patient Population

Patients with adenocarcinoma of the prostate treated primarily with radical prostatectomy; pathologic T-classification pT2 or pT3; pathologic N-classification pN0 or pNX; and no clinical evidence of regional lymph node metastasis.

Target Accrual

282